DSM reports results first nine months 2020
DSM reports a solid first nine months in a challenging COVID-19 environment, with a continuing robust performance in Q3.
03 Nov 2020
Investor event 2020
Videos, presentations & webcast
DSM reports solid first nine months
Robust performance in Q3
Sale of Resins & Functional Materials businesses
DSM continues to evolve
Biomin & Romer Labs join DSM
Businesses acquired from Erber Group
- cmd
- 9-months
- drfm
- erber
Purpose-led, Performance-driven
DSM is a global science-based company operating in the fields of Nutrition, Health and Sustainable Living. Our business is centered around developing innovative solutions and large innovation projects addressing Nutrition & Health, Climate & Energy and Resources & Circularity to drive above market growth.
Why invest in DSM?
DSM is positioned to drive continued above market organic growth and deliver further improvement in profitability, shareholder return and sustainability as we execute Strategy 2021.
Results center
The Annual Results published on 13 February confirm DSM delivered a good financial performance for the year and achieved the key milestones in the first year of its Strategy 2021.
Share center
In 2019 DSM celebrated the 30th anniversary of its privatisation and our ordinary shares being listed on the Euronext Stock Exchange in Amsterdam, the Netherlands.
- NUTRITION
- MATERIALS
Nutrition
We provide nutritional solutions for animal health and human well-being, serving the global feed, food & beverage, pharmaceutical, infant nutrition, dietary supplements and personal care industries.
Animal Nutrition & Health
2019
Sales: ↑€2,892 (2018: €2,749)
Organic Growth: ↑4%
Volume Growth: ↑2%
Price Growth: ↑2%
Human Nutrition
2019
Sales: ↑€2,046 (2018: €1,989)
Organic Growth: ↓1%
Volume Growth: ↑2%
Price Growth: ↓3%
Sales1
€6,028m
Adjusted EBITDA1
€1,250M
Adjusted EBITDA Margin1
20.7%
1) Underlying business, net of temporary vitamin effect
Materials
Advanced and high-performance materials for the electrical & electronics, automotive, packaging, consumer goods, life protection, transportation and telecom industries.
Sales
€2,746M
Adjusted EBITDA
€509M
Adjusted EBITDA Margin
18.5%
Latest financial & regulatory news
-
-
DSM provides preliminary 2019 and 2020 H1 comparative figures
DSM’s Resins & Functional Materials businesses moved to discontinued operations with their agreed sale to Covestro AG.
08 Oct 2020
-
DSM completes acquisition of Erber Group
DSM acquires Erber's Biomin specialty animal nutrition and health & Romer Labs food/feed safety diagnostics businesses.
02 Oct 2020
Our Investor Relations team are based in Heerlen, the Netherlands. The team provides key facts and figures, as well as shareholder information, to current and potential shareholders of DSM and to analysts. To that effect Investor Relations plans, prepares and organizes the written and oral communications with (potential) shareholders and financial analysts, deals with the stock exchange authorities and maintains the necessary databases, websites and brochures.
Dave Huizing
Vice President
Investor Relations
+31 45 578 2864
Sandra Segers
PA to Dave Huizing
Investor Relations
+31 45 578 2864
Anna Morello
Manager
Investor Relations
+31 45 578 2282
Marc Silvertand
Manager
Investor Relations
+31 45 578 2348
Daniel Uribe
Analyst
Investor Relations
+31 45 578 2864
Petra Volk
Support Officer
Investor Relations
+31 45 578 2511
Read more
-
At a glance
Key facts and figures about DSM, our business and our people, planet & profit performance in one overview.
-
Factbooks
An introduction for investors and analysts to DSM, our Nutrition, Materials and Innovation Center clusters and our businesses.
-
Corporate Governance
We believe in doing business the right way: from our management and supervisory boards, to our code of business conduct, to our position papers and statements on key industry issues.